Pallas Capital Advisors LLC Increases Position in Medpace Holdings, Inc. $MEDP

Pallas Capital Advisors LLC lifted its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 154.1% during the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 4,573 shares of the company’s stock after buying an additional 2,773 shares during the quarter. Pallas Capital Advisors LLC’s holdings in Medpace were worth $2,351,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of the company. Quent Capital LLC bought a new stake in Medpace during the third quarter valued at about $25,000. Geneos Wealth Management Inc. grew its position in shares of Medpace by 64.9% during the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after purchasing an additional 37 shares in the last quarter. Employees Retirement System of Texas bought a new stake in Medpace during the 2nd quarter valued at approximately $36,000. Root Financial Partners LLC bought a new stake in Medpace during the 3rd quarter valued at approximately $38,000. Finally, Whittier Trust Co. of Nevada Inc. lifted its holdings in Medpace by 35.1% in the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 104 shares of the company’s stock worth $55,000 after purchasing an additional 27 shares in the last quarter. Institutional investors own 77.98% of the company’s stock.

Analyst Ratings Changes

MEDP has been the subject of a number of research analyst reports. Jefferies Financial Group raised shares of Medpace from a “hold” rating to a “buy” rating and set a $560.00 price objective for the company in a report on Friday. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Medpace in a research note on Wednesday, January 28th. Leerink Partners reduced their price target on shares of Medpace from $575.00 to $485.00 and set a “market perform” rating on the stock in a report on Wednesday, February 11th. Truist Financial dropped their price objective on shares of Medpace from $555.00 to $539.00 and set a “hold” rating for the company in a report on Wednesday, February 11th. Finally, TD Cowen restated a “sell” rating on shares of Medpace in a research report on Friday, October 24th. Four analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and three have issued a Sell rating to the company’s stock. According to data from MarketBeat, Medpace currently has an average rating of “Hold” and a consensus target price of $487.36.

Insider Activity

In other Medpace news, CFO Kevin M. Brady sold 3,000 shares of Medpace stock in a transaction on Friday, November 21st. The shares were sold at an average price of $590.35, for a total transaction of $1,771,050.00. Following the completion of the transaction, the chief financial officer directly owned 6,000 shares of the company’s stock, valued at $3,542,100. The trade was a 33.33% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Susan E. Burwig sold 20,000 shares of the stock in a transaction on Monday, November 24th. The shares were sold at an average price of $609.15, for a total transaction of $12,183,000.00. Following the completion of the sale, the vice president directly owned 27,500 shares in the company, valued at approximately $16,751,625. This represents a 42.11% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 257,295 shares of company stock valued at $155,300,319. 20.30% of the stock is currently owned by insiders.

Medpace Trading Up 2.9%

Shares of NASDAQ MEDP opened at $428.03 on Tuesday. Medpace Holdings, Inc. has a 12-month low of $250.05 and a 12-month high of $628.92. The firm’s 50-day moving average price is $565.10 and its 200-day moving average price is $539.07. The stock has a market capitalization of $12.15 billion, a price-to-earnings ratio of 27.98, a P/E/G ratio of 2.05 and a beta of 1.42.

Medpace (NASDAQ:MEDP) last released its quarterly earnings results on Monday, February 9th. The company reported $4.67 EPS for the quarter, topping the consensus estimate of $4.18 by $0.49. Medpace had a return on equity of 118.82% and a net margin of 17.83%.The company had revenue of $708.45 million during the quarter, compared to analyst estimates of $689.53 million. During the same quarter last year, the business posted $3.67 earnings per share. The firm’s revenue was up 32.0% on a year-over-year basis. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. On average, equities analysts predict that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.